Chart-Typ:
Zeitraum:
| Agios Pharmaceuticals, Inc.: Agios Reports Second Quarter 2026 Financial Results and Provides Business Update | Mitapivat (PYRUKYND and AQVESME) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025Strong U.S. commercial launch... ► Artikel lesen |
| Agios Pharmaceuticals, Inc.: Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease | Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development... ► Artikel lesen |
| Agios Pharmaceuticals, Inc.: U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease | FDA's PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen |
| XFRA 1BT: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
| XFRA 1BT: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILENLIVEX LTD. IS-... ► Artikel lesen |
| XFRA CAPITAL ADJUSTMENT INFORMATION - 27.10.2026 | Das Instrument 4W1 AU000000WCN6 WHITE CLIFF MINERALS LTD. EQUITY wird cum Kapitalmassnahme gehandelt am 27.10.2026 und ex Kapitalmassnahme am 28.10.2026 The instrument 4W1 AU000000WCN6 WHITE CLIFF MINERALS... ► Artikel lesen |
| XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen |
| Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 resultsCash balance of $18.1 million as of... ► Artikel lesen |
| Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELUTIA INC finden Sie auf Wallstreet Online.